Assuntos
Clofazimina/efeitos adversos , Duodenopatias/induzido quimicamente , Eritema Nodoso/tratamento farmacológico , Hansenostáticos/efeitos adversos , Hanseníase Virchowiana/tratamento farmacológico , Adulto , Clofazimina/uso terapêutico , Duodenopatias/patologia , Endoscopia do Sistema Digestório , Humanos , Hansenostáticos/uso terapêutico , Transtornos da Pigmentação/induzido quimicamente , Transtornos da Pigmentação/patologiaRESUMO
A patient on treatment for multibacillary leprosy for the past three years, presented with episodes of abdominal pain. Since the patient improved with conservative management, clofazimine induced enteropathy was considered as a remote possibility. A review of the mucosal biopsies showed macrophages with crystal-storing spaces consistent with clofazimine deposition in the duodenum. This case highlights the need to consider and investigate drug-induced disease as part of the differential diagnosis.
Assuntos
Clofazimina/efeitos adversos , Duodenopatias/induzido quimicamente , Hansenostáticos/efeitos adversos , Duodenopatias/diagnóstico , Gastrite Atrófica/induzido quimicamente , Humanos , Hanseníase Virchowiana/tratamento farmacológico , Masculino , Pessoa de Meia-IdadeRESUMO
Clofazimine, previously used in the treatment of leprosy, is now used for treatment of Mycobacterium avium complex infection in patients with acquired immune deficiency syndrome, dermatologic disorders, and graft-versus-host disease. An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease. Clofazimine enteropathy caused by crystal deposition can be life-threatening.